

Table 3 : Summary of results.

Altered genes	MDSs N = 65 m/t (%)	Secondary AMLs N = 18 m/t (%)	Primary AMLs N = 46 m/t (%)	Total N = 129 m/t (%)
<i>RUNX1</i>	5/65 (7.7)	6/18 (33.3)	4/46 (8.7)	15/129 (11.6)
<i>TET2</i>	13/65 (20)	4/18 (22.2)	5/46 (10.9)	22/129 (17.1)
<i>ASXL1</i>	13/65 (20)	9/18 (50)	3/46 (6.5)	25/129 (19.4)
<i>NPM1</i>	0/65 (0)	2/18 (11.1)	26/46 (56.5)	28/128 (21.9)
<i>CBL</i>	5/65 (7.7)	1/18 (5.5)	0/46 (0)	6/129 (4.7)
<i>FLT3</i>	0/65 (0)	2/18 (11.1)	17/46 (37)	19/129 (14.7)
<i>JAK2</i>	1/65 (1.5)	0/16 (0)	1/45 (2.2)	2/126 (1.6)
<i>RAS (N or K)</i>	1/65 (1.5)	1/18 (5.6)	2/45 (4.4)	4/128 (3.1)
<i>IDH1</i>	2/65 (3.1)	0/18 (0)	3/46 (6.5)	5/129 (3.9)
<i>IDH2</i>	3/65 (4.6)	5/18 (27.8)	10/46 (21.7)	18/129 (14)
<i>IDH1+IDH2</i>	5/65 (7.7)	5/18 (27.8)	13/46 (28.3)	23/129 (17.8)
<i>WT1</i>	0/65 (0)	0/18 (0)	3/46 (6.5)	3/129 (2.3)
0 alteration	33 (50.8)	2 (11)	2 (4.3)	37/129 (28.7)
1alteration	24 (36.9)	4 (22.2)	21 (45.7)	49/129 (38)
2 alterations	7 (10.8)	9 (50)	17 (37)	33/129 (25.6)
3 alterations	2 (3.1)	3 (16.7)	6 (13)	11/129 (8.5)

Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; N, total number of cases; m, number of mutated cases; t, number of tested cases.